Commoney Wise
  • News
  • Politics
  • Business
  • Finance
  • Investing
  • Markets
    • Stocks
    • Commodities
    • Futures
    • Forex
  • Crypto
  • Price Index
    • Stocks
    • Cryptocurrency
    • Commodities
    • Forex
  • Videos
  • Login
  • Register

  Breaking
Crypto Analysts are Saying These Altcoins Have Huge Potential – Here’s Why February 2, 2023
Adani scraps $2.5 billion share sale as value of his empire collapses February 2, 2023
Shell hit with damages claim by 11,000 Nigerians in UK High Court February 2, 2023
The UK finds its way to a tougher line on crypto February 2, 2023
EU warns Elon Musk Twitter must make progress to comply with bloc’s new rules curbing hate speech February 2, 2023
Next
Prev

en English
en Englishes Españolde Deutschfr Françaisit Italianopt Portuguêsru Русскийzh-CN 简体中文hi हिन्दीja 日本語
Casino
  • News
  • Politics
  • Business
  • Finance
  • Investing
  • Markets
    • Stocks
    • Commodities
    • Futures
    • Forex
  • Crypto
  • Price Index
    • Stocks
    • Cryptocurrency
    • Commodities
    • Forex
  • Videos
No Result
View All Result
Commoney Wise
Casino
  • News
  • Politics
  • Business
  • Economy
  • Finance
  • Investing
  • Markets
  • Crypto
  • Tech
  • Videos
Home Business

Moderna and Merck team-up to fight melanoma

Staff by Staff
December 13, 2022
in Business
0 0
A A
0

A Moderna study published Tuesday shows the vaccine-maker’s collaboration with biopharma Merck will help patients fight an aggressive form of skin cancer. 

In a joint release, the companies announced Moderna’s experimental personalized mRNA cancer vaccine and Merck’s immunotherapy drug Keytruda reduced the risk of death or recurrence of stage III/IV melanoma in high-risk patients by 44%, when compared to treatments using only Keytruda.

Melanoma, the most serious form of skin cancer, is characterized by the uncontrolled growth of pigment-producing cells. The five-year survival rates are estimated to be 60.3% for stage III and 16.2% for stage IV.

CAN’T FIND CHILDREN’S TYLENOL? YOU MIGHT NOT NEED IT, DOCTORS SAY

Dr. Dean Y. Li, president of Merck Research Laboratories, said in the release that the positive findings represented an important milestone in the collaboration with Moderna:

“Over the last six years, our teams have worked closely together combining our respective expertise in mRNA and immuno-oncology with a focus on improving outcomes for patients with cancer.” 

Both Moderna and Merck will discuss results with regulatory authorities and initiate a Phase 3 study in melanoma next year while rapidly expanding to additional tumor types.

JUUL LABS WILL PAY $1.2B FOR ROLE IN YOUTH-VAPING EPIDEMIC

Moderna CEO Stéphane Bancel, said the partnership would also bring individualized cancer treatments to patients.

“We look forward to publishing the full data set and sharing the results at an upcoming oncology medical conference, as well as with health authorities,” Bancel added. 

The collaboration was announced in October after Merck exercised its option to jointly develop and commercialize the treatment. 

The rates of melanoma have been rising over the past few decades, with nearly 325,000 new cases diagnosed worldwide in 2020. In the U.S., skin cancer is one of the most common types of cancer diagnosed, and melanoma accounts for a large majority of skin cancer deaths. It is estimated there will be nearly 100,000 new cases of melanoma diagnosed and almost 8,000 deaths resulting from the disease in the U.S. in 2022. 

MODERNA TURNS DOWN CHINA REQUEST FOR VACCINE TECHNOLOGY: REPORT

Ticker Security Last Change Change %
MRNA MODERNA INC. 203.70 +38.57 +23.36%
MRK MERCK & CO. INC. 108.97 +0.19 +0.17%

Read the full article here

ShareTweetSharePinShareSendShare
https://www.madmoneycasino.com/?faff=667&sub=DemCasino

Related Articles

Business

Shell hit with damages claim by 11,000 Nigerians in UK High Court

February 2, 2023
Business

EU warns Elon Musk Twitter must make progress to comply with bloc’s new rules curbing hate speech

February 2, 2023
Business

Goldman to fund meagre payouts to banks hammered by Archegos collapse

February 2, 2023
Business

OpenAI to offer ChatGPT subscription plan for $20 a month

February 1, 2023
Business

KKR set to make offer for Telecom Italia’s fixed-line business

February 1, 2023
Business

Meta shares soar after better than expected revenues of $32.2bn

February 1, 2023
Load More

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Commoney Wise

Commoney Wise is your one stop news website for the latest finance, business and crypto news, follow us to get the news that matters to your minute by minute.

Our Other Brands Kronosslott, Commoneywise, Demcasino.de, SportsExtremes.tv, Slotgamesusawwr, Coin Desk Times, Kingsofgolf.be

Topics

Business Commodities Crypto Economy Finance Forex Futures Investing Markets News Politics Stocks Tech Videos

Get Informed

The most important world news and events of the day

Be the first to know latest important news & events directly to your inbox.

By signing up, I agree to our TOS and Privacy Policy.

  • Privacy
  • Terms
  • Press
  • Advertise
  • Contact

© 2022 Commoney Wise. All Rights Reserved.

No Result
View All Result
  • News
  • Politics
  • Business
  • Finance
  • Investing
  • Markets
    • Stocks
    • Commodities
    • Futures
    • Forex
  • Crypto
  • Price Index
    • Stocks
    • Cryptocurrency
    • Commodities
    • Forex
  • Videos

© 2022 Commoney Wise. All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password? Sign Up

Create New Account!

Fill the forms below to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In
This website uses cookies. By continuing to use this website you are giving consent to cookies being used. Visit our Privacy and Cookie Policy.